Explore

Trendline Trendline
Rocket Pharmaceuticals Reports Financial Results and Advances Gene Therapy Pipeline

Rocket Pharmaceuticals Reports Financial Results and Advances Gene Therapy Pipeline

Rocket Pharmaceuticals Reports Financial Results and Advances Gene Therapy Pipeline
Trendline Trendline
Sarepta Therapeutics Reports Q1 2026 Financial Results Amidst Strategic Developments

Sarepta Therapeutics Reports Q1 2026 Financial Results Amidst Strategic Developments

Sarepta Therapeutics Reports Q1 2026 Financial Results Amidst Strategic Developments
Trendline Trendline
DiaMedica Therapeutics Reports Financial Results and Advances Clinical Trials for Preeclampsia and Stroke

DiaMedica Therapeutics Reports Financial Results and Advances Clinical Trials for Preeclampsia and Stroke

DiaMedica Therapeutics Reports Financial Results and Advances Clinical Trials for Preeclampsia and Stroke
Trendline Trendline
Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline

Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline

Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline
Trendline Trendline
Compass Pathways to Release Q1 2026 Financial Results and Updates

Compass Pathways to Release Q1 2026 Financial Results and Updates

Compass Pathways to Release Q1 2026 Financial Results and Updates
Trendline Trendline
Evommune Reports Q1 2026 Financial Results and Advances Inflammatory Disease Therapies

Evommune Reports Q1 2026 Financial Results and Advances Inflammatory Disease Therapies

Evommune Reports Q1 2026 Financial Results and Advances Inflammatory Disease Therapies
Trendline Trendline
Pierre Fabre Aligns with FDA for Tabelecleucel Resubmission Pathway

Pierre Fabre Aligns with FDA for Tabelecleucel Resubmission Pathway

Pierre Fabre Aligns with FDA for Tabelecleucel Resubmission Pathway
Trendline Trendline
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026
Trendline Trendline
Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results

Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results

Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results
Trendline Trendline
Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market

Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market

Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market
Trendline Trendline
Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings
Trendline Trendline
Madrigal Pharmaceuticals Expands siRNA Pipeline with $1 Billion Deal for MASH Treatment

Madrigal Pharmaceuticals Expands siRNA Pipeline with $1 Billion Deal for MASH Treatment

Madrigal Pharmaceuticals Expands siRNA Pipeline with $1 Billion Deal for MASH Treatment